ASCRS•ASOA Meeting Preview

Meeting Preview 2017

The ASCRS Meeting Program is the most up to date information on the ASCRS Symposium on Cataract, IOL, and Refractive Surgery and the ASOA Congress on Ophthalmic Practice Management and the Technician's and Nurses Program

Issue link:

Contents of this Issue


Page 66 of 66

Right from the beginning, iStent is designed to restore and maintain conventional physiological outfl ow in the trabecular meshwork, and deliver a favorable benefi t-to-risk ratio. Studied extensively around the world, iStent has been implanted in hundreds of thousands of eyes, and is backed by years of documented effi cacy and safety data. For cataract patients with open-angle glaucoma, start with the MIGS leader—and fi nish with leading performance. ASCRS Booth 847 800.GLAUKOS (452.8567) Choose iStent ® —First and foremost. START HERE INDICATION FOR USE. The iStent ® Trabecular Micro-Bypass Stent (Models GTS100R and GTS100L) is indicated for use in conjunction with cataract surgery for the reduction of intraocular pressure (IOP) in adult patients with mild to moderate open-angle glaucoma currently treated with ocular hypotensive medication. CONTRAINDICATIONS. The iStent ® is contraindicated in eyes with primary or secondary angle closure glaucoma, including neovascular glaucoma, as well as in patients with retrobulbar tumor, thyroid eye disease, Sturge-Weber Syndrome or any other type of condition that may cause elevated episcleral venous pressure. WARNINGS. Gonioscopy should be performed prior to surgery to exclude PAS, rubeosis, and other angle abnormalities or conditions that would prohibit adequate visualization of the angle that could lead to improper placement of the stent and pose a hazard. The iStent ® is MR-Conditional meaning that the device is safe for use in a specifi ed MR environment under specifi ed conditions, please see label for details. PRECAUTIONS. The surgeon should monitor the patient postoperatively for proper maintenance of intraocular pressure. The safety and effectiveness of the iStent ® has not been established as an alternative to the primary treatment of glaucoma with medications, in children, in eyes with signifi cant prior trauma, chronic infl ammation, or an abnormal anterior segment, in pseudophakic patients with glaucoma, in patients with pseudoexfoliative glaucoma, pigmentary, and uveitic glaucoma, in patients with unmedicated IOP less than 22 mmHg or greater than 36 mmHg after "washout" of medications, or in patients with prior glaucoma surgery of any type including argon laser trabeculoplasty, for implantation of more than a single stent, after complications during cataract surgery, and when implantation has been without concomitant cataract surgery with IOL implantation for visually signifi cant cataract. ADVERSE EVENTS. The most common post-operative adverse events reported in the randomized pivotal trial included early post-operative corneal edema (8%), BCVA loss of ≥ 1 line at or after the 3 month visit (7%), posterior capsular opacifi cation (6%), stent obstruction (4%) early post-operative anterior chamber cells (3%), and early post-operative corneal abrasion (3%). Please refer to Directions for Use for additional adverse event information. CAUTION: Federal law restricts this device to sale by, or on the order of, a physician. Please reference the Directions for Use labeling for a complete list of contraindications, warnings, precautions, and adverse events. ©2016 Glaukos Corporation. Glaukos and iStent are registered trademarks of Glaukos Corporation. 400-0370-2016-US Rev. 0 The complete procedure. +

Articles in this issue

Links on this page

Archives of this issue

view archives of ASCRS•ASOA Meeting Preview - Meeting Preview 2017